4 analysts have shared their evaluations of NewAmsterdam Pharma (NASDAQ:NAMS) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Analysts have set 12-month price targets for NewAmsterdam Pharma, revealing an average target of $33.75, a high estimate of $37.00, and a low estimate of $31.00. Marking an increase of 2.27%, the current average surpasses the previous average price target of $33…